Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
  • Patent number: 6942965
    Abstract: Hepatitis A virus primers and probes derived from the capsid proteins and junction between the capsid precursor P1 and 2A of the HAV genome are disclosed. Also disclosed are nucleic acid-based assays using the primers and probes, antigen detection of HAV, and immunoassay for detecting the antibodies that bind to HAV.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: September 13, 2005
    Assignee: Chiron Corporation
    Inventors: Sergio Pichuantes, Steve H. Nguyen
  • Patent number: 6861410
    Abstract: The present invention is directed to novel adjuvant compositions, which target the cellular and/or humoral arms of immunity. According to an embodiment of the invention, an oil-in-water adjuvant composition is provided that comprises: (a) water; (b) a metabolizable oil comprising at least one branched or unbranched long-chain hydrocarbon moiety; (c) a steroid; and (d) a saponin.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: March 1, 2005
    Assignee: Chiron Corporation
    Inventors: Gary S. Ott, Derek O'Hagan, Manmohan Singh
  • Patent number: 6830906
    Abstract: Methods and compositions are provided for the production of human manganese superoxide dismutase and a protocol for enhancing efficiency of expression. The gene encoding for human manganese superoxide dismutase was isolated and inserted into a vector in conjunction with a synthetic linker which provides for enhanced efficiency in translation. E. coli strain HB101 containing the plasmid Nco5AHSODm was deposited at the A.T.C.C. on Oct. 3, 1986 and given Accession No. 67191.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: December 14, 2004
    Assignee: Chiron Corporation
    Inventors: Robert Alexander Hallewell, Graeme Ian Bell, Guy Towns Mullenbach
  • Patent number: 6824793
    Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 30, 2004
    Assignees: Chiron Corporation, Fidia Advanced Biopolymers Srl
    Inventors: Derek O'Hagan, Alessandra Pavesio
  • Patent number: 6825333
    Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: November 30, 2004
    Assignee: Chiron Corporation
    Inventors: W. Michael Kavanaugh, Hui Cen, Pauline Lee
  • Patent number: 6818439
    Abstract: Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 105 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.
    Type: Grant
    Filed: December 30, 1997
    Date of Patent: November 16, 2004
    Assignee: Chiron Corporation
    Inventors: Douglas J. Jolly, Stephen Chang, James G. Respess, Nicholas J. DePolo, David Chi-Tang Hsu, Carlos E. Ibanez, Judith Greengard, Lee Will
  • Patent number: 6818222
    Abstract: The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT).
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: November 16, 2004
    Assignee: Chiron Corporation
    Inventors: Gail Barchfeld, Giuseppe Del Giudice, Rino Rappuoli
  • Patent number: 6815160
    Abstract: Imnunoassays for detecting hepatitis C virus protein and immune complexes between hepatitis C virus protein and antibodies in biological samples, methods of screening blood products for hepatitis C virus, and kits employed therefor are provided.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: November 9, 2004
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, Phillip Arcangel
  • Patent number: 6809194
    Abstract: Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: October 26, 2004
    Assignee: Chiron Corporation
    Inventors: Christoph Reinhard, Anne B. Jefferson
  • Patent number: 6806360
    Abstract: A cDNA clone having a base sequence for human tissue factor inhibitor (TFI) has been developed and characterized and the amino acid sequence of the TFI has been determined.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: October 19, 2004
    Assignee: G.D. Searle & Co.
    Inventors: Tze Chein Wun, Kuniko K. Kretzmer, George J. Broze, Jr.
  • Patent number: 6800760
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: October 5, 2004
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
  • Patent number: 6800632
    Abstract: New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: October 5, 2004
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Xiaohui A. Zhou
  • Patent number: 6797809
    Abstract: HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: September 28, 2004
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, Phillip Arcangel, Laura Tandeske, Carlos George-Nascimento, Doris Coit, Angelica Medina-Selby
  • Patent number: 6797695
    Abstract: This invention relates to human fibroblast growth factor (hFGF-20), and to variants thereof and to polynucleotides encoding FGF-20. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, to methods of treating neuronal degenerative disease such as Parkinson's disease and to methods of treating disorders of the cochlea including those causing hearing loss. The invention also relates to rat fibroblast growth factor (rFGF-20), and to variants thereof and polynucleotides encoding rFGF-20.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: September 28, 2004
    Assignees: Kyoto University, Chiron Corporation
    Inventors: Nobuyuki Itoh, Michael Kavanaugh
  • Patent number: 6783929
    Abstract: Provided are affinity support materials having intermediate binding affinity for biological samples. Among the materials provided by the present invention are hydrophilic solid supports composed of hydrophilic ligands coupled to hydrophilic matrixes which are compatible with biological samples, for example, a cell line, a biological fluid such as blood, or a tissue cell lysate. The ligands may include affinity property groups and hydrophilic groups pendent from a backbone, and be configured to at least partially resolve components of a biological sample. Affinity supports in accordance with the present invention may be used in a variety of techniques and apparatuses to achieve improved separations of complex biological samples and thereby enhance the results of biological sample component fractionations, enrichments, purifications, expression product determinations and comparisons, and other biological sample processing techniques.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: August 31, 2004
    Assignee: Chiron Corporation
    Inventors: Ronald N. Zuckermann, Eric Beausoleil, Matthew Wachowicz, Srinivas Kothakota
  • Patent number: 6783960
    Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: August 31, 2004
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Abla A. Creasey
  • Patent number: 6777538
    Abstract: A 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purification of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: August 17, 2004
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Patent number: 6774237
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 10, 2004
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
  • Patent number: 6767699
    Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: July 27, 2004
    Assignee: Chiron Corporation
    Inventors: John M. Polo, Catherine Greer, Thomas W. Dubensky, Jr.
  • Patent number: 6762194
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: July 13, 2004
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Eliza Jazan